共有 50 笔近期内部人交易记录记录，涉及 ANI Pharmaceuticals, Inc. (ANIP), 包括 9 笔买入 和 41 笔卖出. 内部人买入总额为 $14.28M 内部人卖出总额为 $10.77M.
近期活跃的重要内部人包括 Mutz Christopher, Cook Meredith, Rowland Thomas Andrew. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — ANIP
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-13 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
3,162 |
$71.64 |
$226.53K |
91,309 |
| 2026-03-13 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
知情卖出 |
500 |
$72.62 |
$36.31K |
79,390 |
| 2026-03-11 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
知情卖出 |
4,772 |
$74.91 |
$357.47K |
38,730 |
| 2026-03-09 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
3,602 |
$74.18 |
$267.2K |
94,471 |
| 2026-03-09 |
Davis Krista |
SVP, Chief HR Officer |
知情卖出 |
5,087 |
$74.13 |
$377.1K |
51,946 |
| 2026-03-07 |
Carey Stephen P. |
SVP & CFO |
RSU 预扣税 |
5,150 |
$74.04 |
$381.31K |
180,393 |
| 2026-03-07 |
Lalwani Nikhil |
President & CEO |
RSU 预扣税 |
17,060 |
$74.04 |
$1.26M |
404,889 |
| 2026-03-07 |
Gutwerg Ori |
SVP, Generics |
RSU 预扣税 |
3,314 |
$74.04 |
$245.37K |
81,468 |
| 2026-03-07 |
Mutz Christopher |
Head of Rare Disease |
RSU 预扣税 |
3,314 |
$74.04 |
$245.37K |
98,073 |
| 2026-03-06 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
2,121 |
$74.22 |
$157.42K |
101,387 |
| 2026-03-06 |
Davis Krista |
SVP, Chief HR Officer |
知情卖出 |
1,485 |
$75.00 |
$111.38K |
57,033 |
| 2026-03-05 |
Carey Stephen P. |
SVP & CFO |
期权行权（卖出） |
3,312 |
$49.51 |
$163.98K |
9,938 |
| 2026-03-03 |
Walsh Patrick D |
Director |
知情卖出 |
6,000 |
$74.23 |
$445.38K |
52,405 |
| 2026-03-03 |
Gutwerg Ori |
SVP, Generics |
知情卖出 |
2,060 |
$76.50 |
$157.59K |
84,782 |
| 2026-03-02 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
417 |
$74.00 |
$30.86K |
103,508 |
| 2026-02-28 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 预扣税 |
628 |
$73.90 |
$46.41K |
43,502 |
| 2026-02-28 |
Carey Stephen P. |
SVP & CFO |
RSU 预扣税 |
2,773 |
$73.90 |
$204.92K |
189,543 |
| 2026-02-28 |
Lalwani Nikhil |
President & CEO |
RSU 预扣税 |
12,217 |
$73.90 |
$902.84K |
421,949 |
| 2026-02-28 |
Gutwerg Ori |
SVP, Generics |
RSU 预扣税 |
2,221 |
$73.90 |
$164.13K |
86,842 |
| 2026-02-28 |
Mutz Christopher |
Head of Rare Disease |
RSU 预扣税 |
2,221 |
$73.90 |
$164.13K |
103,925 |
| 2026-02-28 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 预扣税 |
2,221 |
$73.90 |
$164.13K |
74,916 |
| 2026-02-28 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU 预扣税 |
1,555 |
$73.90 |
$114.91K |
79,890 |
| 2026-02-28 |
Davis Krista |
SVP, Chief HR Officer |
RSU 预扣税 |
1,555 |
$73.90 |
$114.91K |
58,518 |
| 2026-02-26 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
限制性股票授予 (RSU) |
6,021 |
$77.15 |
$464.52K |
44,130 |
| 2026-02-26 |
Carey Stephen P. |
SVP & CFO |
限制性股票授予 (RSU) |
22,233 |
$77.15 |
$1.72M |
192,316 |
| 2026-02-26 |
Lalwani Nikhil |
President & CEO |
限制性股票授予 (RSU) |
75,592 |
$77.15 |
$5.83M |
434,166 |
| 2026-02-26 |
Gutwerg Ori |
SVP, Generics |
限制性股票授予 (RSU) |
12,969 |
$77.15 |
$1M |
89,063 |
| 2026-02-26 |
Mutz Christopher |
Head of Rare Disease |
限制性股票授予 (RSU) |
21,306 |
$77.15 |
$1.64M |
106,146 |
| 2026-02-26 |
Shanmugam Muthusamy |
Head of R&d, COO-novitium Ops |
限制性股票授予 (RSU) |
11,116 |
$77.15 |
$857.6K |
101,056 |
| 2026-02-26 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
限制性股票授予 (RSU) |
11,116 |
$77.15 |
$857.6K |
77,137 |
| 2026-02-26 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
限制性股票授予 (RSU) |
13,895 |
$77.15 |
$1.07M |
81,445 |
| 2026-02-26 |
Davis Krista |
SVP, Chief HR Officer |
限制性股票授予 (RSU) |
10,810 |
$77.15 |
$833.99K |
60,073 |
| 2026-02-20 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
5,323 |
$78.02 |
$415.3K |
84,840 |
| 2026-02-20 |
Davis Krista |
SVP, Chief HR Officer |
知情卖出 |
1,730 |
$77.99 |
$134.92K |
49,263 |
| 2026-02-19 |
Davis Krista |
SVP, Chief HR Officer |
知情卖出 |
2,084 |
$77.53 |
$161.57K |
50,993 |
| 2026-02-14 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 预扣税 |
485 |
$77.36 |
$37.52K |
38,109 |
| 2026-02-14 |
Carey Stephen P. |
SVP & CFO |
RSU 预扣税 |
2,448 |
$77.36 |
$189.38K |
170,083 |
| 2026-02-14 |
Lalwani Nikhil |
President & CEO |
RSU 预扣税 |
10,298 |
$77.36 |
$796.65K |
358,574 |
| 2026-02-14 |
Gutwerg Ori |
SVP, Generics |
RSU 预扣税 |
1,888 |
$77.36 |
$146.06K |
76,094 |
| 2026-02-14 |
Mutz Christopher |
Head of Rare Disease |
RSU 预扣税 |
2,403 |
$77.36 |
$185.9K |
90,163 |
| 2026-02-14 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 预扣税 |
1,717 |
$77.36 |
$132.83K |
66,021 |
| 2026-02-14 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU 预扣税 |
1,779 |
$77.36 |
$137.62K |
67,550 |
| 2026-02-14 |
Davis Krista |
SVP, Chief HR Officer |
RSU 预扣税 |
1,290 |
$77.36 |
$99.79K |
53,077 |
| 2026-02-13 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
知情卖出 |
500 |
$76.80 |
$38.4K |
69,329 |
| 2026-02-12 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 预扣税 |
566 |
$76.70 |
$43.41K |
38,594 |
| 2026-02-12 |
Carey Stephen P. |
SVP & CFO |
RSU 预扣税 |
2,829 |
$76.70 |
$216.98K |
172,531 |
| 2026-02-12 |
Lalwani Nikhil |
President & CEO |
RSU 预扣税 |
11,688 |
$76.70 |
$896.47K |
368,872 |
| 2026-02-12 |
Gutwerg Ori |
SVP, Generics |
RSU 预扣税 |
1,775 |
$76.70 |
$136.14K |
77,982 |
| 2026-02-12 |
Mutz Christopher |
Head of Rare Disease |
知情卖出 |
7,032 |
$76.55 |
$538.3K |
92,566 |
| 2026-02-12 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 预扣税 |
1,608 |
$76.70 |
$123.33K |
67,738 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
